Treatment strategies for inherited optic neuropathies: Past, present and future

Eye (Basingstoke)

Volumn 28, Issue 5, 2014, Pages 521-537

  Yu Wai Man, P ^a,b,c,d   Votruba, M ^e,f   Moore, A T ^c,d   Chinnery, P F ^a,b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b ROYAL VICTORIA INFIRMARY   (United Kingdom)

^c MOORFIELDS EYE HOSPITAL   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e CARDIFF UNIVERSITY   (United Kingdom)

^f UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; ASCORBIC ACID; CARNITINE; CREATINE; CYCLOSPORIN A; IDEBENONE; MITOCHONDRIAL DNA; RIBOFLAVIN; THIOCTIC ACID; VATIQUINONE;

ARTICLE; AUTOSOMAL DOMINANT OPTIC ATROPHY; BLINDNESS; CELL DEATH; CLINICAL FEATURE; CLINICAL PRACTICE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; GENETIC COUNSELING; HUMAN; HYPERBARIC OXYGEN; LEBER HEREDITARY OPTIC NEUROPATHY; MITOCHONDRIAL DNA REPLICATION; MITOCHONDRIAL GENETICS; MITOCHONDRIAL MEMBRANE; NERVE DEGENERATION; NONHUMAN; PENETRANCE; PHENOTYPE; PHOTOTHERAPY; POINT MUTATION; RETINA GANGLION CELL; SEX DIFFERENCE; VISUAL IMPAIRMENT;

EID: 85005790406     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2014.37     Document Type: Article

References (100)

1. Yu-Wai-Man P, Griffiths PG, Chinnery PF. Mitochondrial optic neuropathies-Disease mechanisms and therapeutic strategies. Prog Retinal Eye Res 2011; 30(2): 81-114.
2. Fraser JA, Biousse V, Newman NJ. The Neuroophthalmology of mitochondrial disease. Survey Ophthalmol 2010; 55(4): 299-334.
3. Carelli V, Ross-Cisneros FN, Sadun AA. Mitochondrial dysfunction as a cause of optic neuropathies. Prog Retinal Eye Res 2004; 23(1): 53-89.
4. DiMauro S, Schon EA. Mechanisms of disease: Mitochondrial respiratory-chain diseases. New Engl J Med 2003; 348(26): 2656-2668.
5. Schapira AHV. Mitochondrial diseases. Lancet 2012; 379(9828): 1825-1834.
6. McFarland R, Taylor RW, Turnbull DM. A neurological perspective on mitochondrial disease. Lancet Neurol 2010; 9(8): 829-840.
7. Cree LM, Samuels DC, Lopes SCdS, Rajasimha HK, Wonnapinij P, Mann JR et al. A reduction of mitochondrial DNA molecules during embryogenesis explains the rapid segregation of genotypes. Nat Genet 2008; 40(2): 249-254.
8. Holt IJ, Harding AE, Morganhughes JA. Deletions ofMuscle Mitochondrial-DNA in Patients with Mitochondrial Myopathies. Nature 1988; 331(6158): 717-719.
9. Wallace DC, Singh G, Lott MT, Hodge JA, Schurr TG, Lezza AMS et al. Mitochondrial-DNA Mutation Associated with Lebers Hereditary Optic Neuropathy. Science 1988; 242(4884): 1427-1430.
10. Hudson G, Chinnery PF, Mitochondrial DNA. polymerasegamma and human disease. Hum Mol Genet 2006; 15: R244-R252.
11. Holt IJ, He J, Mao C-C, Boyd-Kirkup JD, Martinsson P, Sembongi H et al. Mammalian mitochondrial nucleoids: organizing an independently minded genome. Mitochondrion 2007; 7(5): 311-321.
12. Man PYW, Griffiths PG, Brown DT, Howell N, Turnbull DM, Chinnery PF. The epidemiology of Leber hereditary optic neuropathy in the North East of England. Am J Hum Genet 2003; 72(2): 333-339.
13. Spruijt L, Kolbach DN, de Coo RF, Plomp AS, Bauer NJ, Smeets HJ et al. Influence of mutation type on clinical expression of Leber hereditary optic neuropathy. Am J Ophthalmol 2006; 141(4): 676-682.
14. Puomila A, Hamalainen P, Kivioja S, Savontaus M-L, Koivumaki S, Huoponen K et al. Epidemiology and penetrance of Leber hereditary optic neuropathy in Finland. Eur J Hum Genet 2007; 15(10): 1079-1089.
15. Macmillan C, Johns TA, Fu K, Shoubridge EA. Predominance of the T14484C mutation in French-Canadian families with Leber hereditary optic neuropathy is due to a founder effect. Am J Hum Genet 2000; 66(1): 332-335.
16. Sitarz KS, Chinnery PF, Yu-Wai-Man P. Disorders of the optic nerve in mitochondrial cytopathies: new ideas on pathogenesis and therapeutic targets. Curr Neurol Neurosci Rep 2012; 12(3): 308-317.
17. Nikoskelainen E. Ophthalmological findings in leber hereditary optic neuropathy, with special reference to the mtDNA mutations (vol 103, pg 504, 1996). Ophthalmology 1996; 103(7): 998.
18. Savini G, Barboni P, Valentino ML, Montagna P, Cortelli P, De Negri AM et al. Retinal nerve fiber layer evaluation by optical coherence tomography in unaffected carriers with Lebers hereditary optic neuropathy mutations. Ophthalmology 2005; 112(1): 127-131.
19. Sadun AA, Salomao SR, Berezovsky A, Sadun F, Denegri AM, Quiros PA et al. Subclinical carriers and conversions in Leber hereditary optic neuropathy: a prospective psychophysical study. Transact Am Ophthalmol Soc 2006; 104: 51-61.
20. Yu-Wai-Man P, Griffiths PG, Hudson G, Chinnery PF. Inherited mitochondrial optic neuropathies. J Med Genet 2009; 46(3): 145-158.
21. La Morgia C, Ross-Cisneros FN, Sadun AA, Hannibal J, Munarini A, Mantovani Vet al. Melanopsin retinal ganglion cells are resistant to neurodegeneration in mitochondrial optic neuropathies. Brain 2010; 133: 2426-2438.
22. Kirkman MA, Korsten A, Leonhardt M, Dimitriadis K, De Coo IF, Klopstock Tet al. Quality of Life in Patients with Leber Hereditary Optic Neuropathy. Invest Ophthalmol Vis Sci 2009; 50(7): 3112-3115.
23. Harding AE, Sweeney MG, Govan GG, Riordaneva P. Pedigree Analysis in Leber Hereditary Optic Neuropathy Families with a Pathogenic Mtdna Mutation. Am J Hum Genet 1995; 57(1): 77-86.
24. Macmillan C, Kirkham T, Fu K, Allison V, Andermann E, Chitayat D et al. Pedigree analysis of French Canadian families with T14484C Lebers hereditary optic neuropathy. Neurology 1998; 50(2): 417-422.
25. Johns DR, Heher KL, Miller NR, Smith KH. Lebers hereditary optic neuropathy-clinical manifestations of the 14484 MUTATION. Arch Ophthalmol 1993; 111(4): 495-498.
26. Barboni P, Savini G, Valentino ML, La Morgia C, Bellusci C, De Negri AM et al. Lebers hereditary optic neuropathy with childhood onset. Invest Ophthalmol Vis Sci 2006; 47(12): 5303-5309.
27. Ramos CdVF, Bellusci C, Savini G, Carbonelli M, Berezovsky A, Tamaki C et al. Association of optic disc size with development and prognosis of Lebers hereditary optic neuropathy. Invest Ophthalmol Vis Sci 2009; 50(4): 1666-1674.
28. Harding AE, Sweeney MG, Miller DH, Mumford CJ, Kellarwood H, Menard D et al. Occurrence of a multiple sclerosis-like illness in women who have a Lebers hereditary optic neuropathy mitochondrial-dna mutation. Brain 1992; 115(4): 979-989.
29. Palace J. Multiple sclerosis associated with Lebers hereditary optic neuropathy. J Neurol Sci 2009; 286(1-2): 24-27.
30. Pfeffer G, Burke A, Yu-Wai-Man P, Compston DA, Chinnery PF. Clinical features of MS associated with Leber hereditary optic neuropathy mtDNA mutations. Neurology 2013; 81(24): 2073-2081.
31. Chinnery PF, Andrews RM, Turnbull DM, Howell N. Leber hereditary optic neuropathy: Does heteroplasmy influence the inheritance and expression of the G11778A mitochondrial DNA mutation? Am J Med Genet 2001; 98(3): 235-243
32. Gomez-Duran A, Pacheu-Grau D, Lopez-Gallardo E, Diez-Sanchez C, Montoya J, Lopez-Perez MJ et al. Unmasking the causes of multifactorial disorders: OXPHOS differences between mitochondrial haplogroups. Hum Mol Genet 2010; 19(17): 3343-3353.
33. Gomez-Duran A, Pacheu-Grau D, Martinez-Romero I, Lopez-Gallardo E, Lopez-Perez MJ, Montoya J et al. Oxidative phosphorylation differences between mitochondrial DNA haplogroups modify the risk of Lebers hereditary optic neuropathy. Biochim Biophys Acta 2012; 1822(8): 1216-1222.
34. Hudson G, Carelli V, Spruijt L, Gerards M, Mowbray C, Achilli A et al. Clinical expression of Leber hereditary optic neuropathy is affected by themitochondrial DNA-haplogroup background. Am J Hum Genet 2007; 81(2): 228-233.
35. Ji Y, Zhang AM, Jia X, Zhang Y-P, Xiao X, Li S et al. Mitochondrial DNA Haplogroups M7b1 2 and M8a affect clinical expression of Leber hereditary optic neuropathy in Chinese families with the m.11778G -4 A mutation. Am J Hum Genet 2008; 83(6): 760-768.
36. Tharaphan P, Chuenkongkaew WL, Luangtrakool K, Sanpachudayan T, Suktitipat B, Suphavilai R et al. Mitochondrial DNA haplogroup distribution in pedigrees of Southeast Asian G11778A Leber hereditary optic neuropathy. J Neuro-Ophthalmol 2006; 26(4): 264-267.
37. Bu XD, Rotter JI. X-chromosome-linked and mitochondrial gene-control of Leber hereditary optic neuropathy- evidence from segregation analysis for dependence on X-chromosome inactivation. Proc Natl Acad Sci USA 1991; 88(18): 8198-8202.
38. Hudson G, Keers S, Man PYW, Griffiths P, Huoponen K, Savontaus ML et al. Identification of an X-chromosomal locus and haplotype modulating the phenotype of a mitochondrial DNA disorder. Am J Hum Genet 2005; 77(6): 1086-1091.
39. Shankar SP, Fingert JH, Carelli V, Valentino ML, King TM, Daiger SP et al. Evidence for a novel x-linked modifier locus for leber hereditary optic neuropathy. Ophthalmic Genet 2008; 29(1): 17-24.
40. Ji Y, Jia X, Li S, Xiao X, Guo X, Zhang Q. Evaluation of the X-linked modifier loci for Leber hereditary optic neuropathy with the G11778A mutation in Chinese. Mol Vision 2010; 16(47): 416-424.
41. Giordano C, Montopoli M, Perli E, Orlandi M, Fantin M, Ross-Cisneros FN et al. Oestrogens ameliorate mitochondrial dysfunction in Lebers hereditary optic neuropathy. Brain 2011; 134: 220-234.
42. Kirkman MA, Yu-Wai-Man P, Korsten A, Leonhardt M, Dimitriadis K, De Coo IF et al. Gene-environment interactions in Leber hereditary optic neuropathy. Brain 2009; 132: 2317-2326.
43. Sadun AA, Win PH, Ross-Cisneros FN, Walker SO, qCarelli V. Lebers hereditary optic neuropathy differentially affects smaller axons in the optic nerve. Transact Am Ophthalmol Soc 2000; 98: 223-235.
44. Carelli V, Rugolo M, Sgarbi G, Ghelli A, Zanna C, Baracca A et al. Bioenergetics shapes cellular death pathways in Lebers hereditary optic neuropathy: a model of mitochondrial neurodegeneration. Biochim Biophys Acta 2004; 1658(1-2): 172-179.
45. Lin CS, Sharpley MS, Fan W, Waymire KG, Sadun AA, Carelli V et al. Mouse mtDNA mutant model of Leber hereditary optic neuropathy. Proc Natl Acad Sci USA 2012; 109(49): 20065-20070.
46. Yu-Wai-Man P, Chinnery PF. Dominant optic atrophy- Novel OPA1 mutations and revised prevalence estimates. Ophthalmology 2013; 120(8): 1712.
47. Alexander C, VotrubaM, PeschUEA, ThiseltonDL, Mayer S, Moore A et al. Identification of the gene responsible for dominant optic atrophy (OPA1) on chromosome 3q28. Am J Hum Genet 2000; 67(4): 40.
48. Delettre C, Lenaers G, Griffoin JM, Gigarel N, Lorenzo C, Belenguer P et al. Nuclear gene OPA1, encoding a mitochondrial dynamin-related protein, is mutated in dominant optic atrophy. Nat Genet 2000; 26(2): 207-210.
49. Ferre M, Bonneau D, Milea D, Chevrollier A, Verny C, Dollfus H et al. Molecular screening of 980 cases of suspected hereditary optic neuropathy with a report on 77 novel OPA1 mutations. Hum Mut 2009; 30(7): E692-E705.
50. Marchbank NJ, Craig JE, Leek JP, Toohey M, Churchill AJ, Markham AF et al. Deletion of the OPA1 gene in a dominant optic atrophy family: evidence that haploinsufficiency is the cause of disease. J Med Genet 2002; 39(8): e47.
51. Yu-Wai-Man P, Griffiths PG, Burke A, Sellar PW, Clarke MP, Gnanaraj L et al. The prevalence and natural history of dominant optic atrophy due to OPA1 mutations. Ophthalmology 2010; 117(8): 1538-1546, 1546.e1.
52. Yu-Wai-Man P, BailieM, Atawan A, Chinnery PF, Griffiths PG. Pattern of retinal ganglion cell loss in dominant optic atrophy due to OPA1 mutations. Eye 2011; 25(5): 597-601.
53. Yu-Wai-Man P, Griffiths PG, Gorman GS, Lourenco CM, Wright AF, Auer-Grumbach M et al. Multi-system neurological disease is common in patients with OPA1 mutations. Brain 2010; 133: 771-786.
54. Lenaers G, Olichon A, Delettre C, Hamel C, Belenguer P. Functions and dysfunctions of the human dynamin OPA1. Biochim Biophys Acta 2004; 1657: 37.
55. Chevrollier A, Guillet V, Loiseau D, Gueguen N, de Crescenzo M-AP, Verny C et al. Hereditary optic neuropathies share a common mitochondrial coupling defect. Ann Neurol 2008; 63(6): 794-798.
56. Zanna C, Ghelli A, Porcelli AM, Karbowski M, Youle RJ, Schimpf S et al. OPA1 mutations associated with dominant optic atrophy impair oxidative phosphorylation and mitochondrial fusion. Brain 2008; 131: 352-367.
57. Frezza C, Cipolat S, de Brito OM, Micaroni M, Beznoussenko GV, Rudka T et al. OPA1 controls apoptotic cristae remodeling independently from mitochondrial fusion. Cell 2006; 126(1): 177-189.
58. Kushnareva YE, Gerencser AA, Bossy B, Ju WK, White AD, Waggoner J et al. Loss of OPA1 disturbs cellular calcium homeostasis and sensitizes for excitotoxicity. Cell DeathDiffer 2013; 20(2): 353-365.
59. Yu-Wai-Man P, Sitarz KS, Samuels DC, Griffiths PG, Reeve AK, Bindoff LA et al. OPA1 mutations cause cytochrome c oxidase deficiency due to loss of wild-type mtDNA molecules. Hum Mol Genet 2010; 19(15): 3043-3052.
60. Bailie M, Votruba M, Griffiths PG, Chinnery PF, Yu-Wai-Man P. Visual and psychological morbidity among patients with autosomal dominant optic atrophy. Acta ophthalmol 2013; 91(5): e413-e414.
61. Pfeffer G, Majamaa K, Turnbull DM, Thorburn D, Chinnery PF. Treatment for mitochondrial disorders. Cochrane Database Syst Rev 2012; 4: CD004426.
62. Pfeffer G, Horvath R, Klopstock T, Mootha VK, Suomalainen A, Koene S et al. New treatments for mitochondrial disease-no time to drop our standards. Nat Rev Neurol 2013; 9(8): 474-481.
63. Newman NJ. Treatment of hereditary optic neuropathies. Nat Rev Neurol 2012; 8(10): 545-556.
64. Huang CC, Kuo HC, Chu CC, Kao LY. Rapid visual recovery after coenzyme Q10 treatment of Leber Hereditary Optic Neuropathy. J Neuro-Ophthalmol 2002; 22(1): 66.
65. Sadun AA, Chicani CF, Ross-Cisneros FN, Barboni P, Thoolen M, Shrader WD et al. Effect of EPI-743 on the clinical course of the mitochondrial disease Leber hereditary optic neuropathy. Arch Neurol 2012; 69(3): 331-338.
66. Mashima Y, Hiida Y, Oguchi Y. Remission of Lebers hereditary optic neuropathy with Idebenone. Lancet 1992; 340(8815): 368-369.
67. Mashima Y, Kigasawa K, Wakakura M, Oguchi Y. Do idebenone and vitamin therapy shorten the time to achieve visual recovery in Leber hereditary optic neuropathy? J Neuro-Ophthalmol 2000; 20(3): 166-170.
68. Barnils N, Mesa E, Munoz S, Ferrer-Artola A, Arruga J. Response to idebenone and multivitamin therapy in Lebers hereditary optic neuropathy. Arch de la Sociedad Espanola de Oftalmol 2007; 82(6): 377-380.
69. Klopstock T, Metz G, Yu-Wai-Man P, Buechner B, Gallenmueller C, Bailie M et al. Persistence of the treatment effect of idebenone in Lebers hereditary optic neuropathy. Brain 2013; 136: e230.
70. Carelli V, LaMorgia C, ValentinoML, RizzoG,CarbonelliM, De Negri AM et al. Idebenone treatment in Lebers hereditary optic neuropathy. Brain 2011; 134: e188.
71. Limb GA, Martin KR. Current prospects in optic nerve protection and regeneration: sixth ARVO/Pfizer Ophthalmics Research Institute Conference. Invest Ophthalmol Vis Sci 2011; 52(8): 5941-5954.
72. Newman NJ, Biousse V, David R, Bhatti MT, Hamilton SR, Farris BK et al. Prophylaxis for second eye involvement in Leber hereditary optic neuropathy: An open-labeled, nonrandomized multicenter trial of topical brimonidine purite. Am J Ophthalmol 2005; 140(3): 407-415.
73. Thouin A, Griffiths PG, Hudson G, Chinnery PF, Yu-Wai-Man P. Raised intraocular pressure as a potential risk factor for visual loss in Leber hereditary optic neuropathy. Plos ONE 2013; 8(5): e63446.
74. Wong A, Cortopassi G. mtDNA Mutations confer cellular sensitivity to oxidant stress that is partially rescued by calcium depletion and cyclosporin A. Biochem Biophys Res Commun 1997; 239(1): 139-145.
75. Porcelli AM, Angelin A, Ghelli A, Mariani E, Martinuzzi A, Carelli V et al. Respiratory complex I dysfunction due to mitochondrial DNA mutations shifts the voltage threshold for opening of the permeability transition pore toward resting levels. J Biol Chem 2009; 284(4): 2045-2052.
76. Malik A, Golnik K. Hyperbaric oxygen therapy in the treatment of radiation optic neuropathy. J Neuro-Ophthalmol 2012; 32(2): 128-131.
77. Desmet KD, Paz DA, Corry JJ, Eells JT, Wong-Riley MTT, Henry MM et al. Clinical and experimental applications of NIR-LED photobiomodulation. Photomed Laser Surg 2006; 24(2): 121-128.
78. Barboni P, Valentino ML, La Morgia C, Carbonelli M, Savini G, De Negri A et al. Idebenone treatment in patients with OPA1-mutant dominant optic atrophy. Brain 2013; 136: e231.
79. Davies VJ, Hollins AJ, Piechota MJ, Yip W, Davies JR, White KE et al. Opa1 deficiency in a mouse model of autosomal dominant optic atrophy impairs mitochondrial morphology, optic nerve structure and visual function. Hum Mol Genet 2007; 16(11): 1307-1318.
80. Levin LA. Axonal loss and neuroprotection in optic neuropathies. Can J Ophthalmol 2007; 42(3): 403-408.
81. Pesce V, Fracasso F, Cassano P, Lezza AMS, Cantatore P, Gadaleta MN. Acetyl-L-carnitine supplementation to old rats partially reverts the age-related mitochondrial decay of soleus muscle by activating peroxisome proliferatoractivated receptor gamma coactivator-1 alpha-dependent mitochondrial biogenesis. Rejuv Res 2010; 13(2-3): 148-151.
82. Pesce V, Nicassio L, Fracasso F, Musicco C, Cantatore P, Gadaleta MN. Acetyl-L-carnitine activates the peroxisome proliferator-Activated receptor-gamma coactivators PGC-1 alpha/PGC-1 beta-dependent signaling cascade of mitochondrial biogenesis and decreases the oxidized peroxiredoxins content in old rat liver. Rejuv Res 2012; 15(2): 136-139.
83. Guy J. New therapies for optic neuropathies: development in experimental models. Curr Opin Ophthalmol 2000; 11(6): 421-429.
84. Guy J, Qi XP, Pallotti F, Schon EA,Manfredi G, Carelli Vet al. Rescue of a mitochondrial deficiency causing Leber hereditary optic neuropathy. Ann Neurol 2002; 52(5): 534-542.
85. Ellouze S, Augustin S, Bouaita A, Bonnet C, Simonutti M, Forster V et al. Optimized allotopic expression of the human mitochondrial ND4 prevents blindness in a rat model of mitochondrial dysfunction. Am J Hum Genet 2008; 83(3): 373-387.
86. Guy J, Qi X, Koilkonda RD, Arguello T, Chou T-H, RuggeriM et al. Efficiency and safety of AAV-mediated gene delivery of the human ND4 complex I subunit in the mouse visual system. Invest Ophthalmol Vis Sci 2009; 50(9): 4205-4214.
87. Qi X, Sun L, Hauswirth WW, Lewin AS, Guy J. Use of mitochondrial antioxidant defenses for rescue of cells with a Leber hereditary optic neuropathy-causing mutation. Arch Ophthalmol 2007; 125(2): 268-272.
88. Seo BB, Nakamaru-Ogiso E, Flotte TR, Matsuno-Yagi A, Yagi T. In vivo complementation of complex I by the yeast Ndi1 enzyme-Possible application for treatment of Parkinson disease. J Biol Chem 2006; 281(20): 14250-14255.
89. Iyer S, Bergquist K, Young K, Gnaiger E, Rao RR, Bennett JP Jr. Mitochondrial gene therapy improves respiration, biogenesis, and transcription in G11778A Lebers hereditary optic neuropathy and T8993G Leighs syndrome cells. Hum Gene Ther 2012; 23(6): 647-657.
90. Yu H, Koilkonda RD, Chou T-H, Porciatti V, Ozdemir SS, Chiodo V et al. Gene delivery to mitochondria by targeting modified adenoassociated virus suppresses Lebers hereditary optic neuropathy in a mouse model. Proc Natl Acad Sci USA 2012; 109(20): E1238-E1247.
91. Yu H, Mehta A, Wang G, Hauswirth WW, Chiodo V, Boye SL et al. Next-generation sequencing of mitochondrial targeted AAV transfer of human ND4 in mice. Mol Vision 2013; 19: 1482-1491.
92. Sarzi E, Angebault C, Seveno M, Gueguen N, Chaix B, Bielicki G et al. The human OPA1(delTTAG) mutation induces premature age-related systemic neurodegeneration in mouse. Brain 2012; 135: 3599-3613.
93. Marchetti V, Krohne TU, Friedlander DF, Friedlander M. Stemming vision loss with stem cells. J Clin Invest 2010; 120(9): 3012-3021.
94. Dahlmann-Noor A, Vijay S, Jayaram H, Limb A, Khaw PT. Current approaches and future prospects for stem cell rescue and regeneration of the retina and optic nerve. Can J Ophthalmol 2010; 45(4): 333-341.
95. Johnson TV, Bull ND, Hunt DP, Marina N, Tomarev SI, Martin KR. Neuroprotective effects of intravitreal mesenchymal stem cell transplantation in experimental glaucoma. Invest Ophthalmol Vis Sci 2010; 51(4): 2051-2059.
96. Connick P, Kolappan M, Crawley C, Webber DJ, Patani R, Michell AW et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept study. Lancet Neurol 2012; 11(2): 150-156.
97. Craven L, Elson JL, Irving L, Tuppen HA, Lister LM, Greggains GD et al. Mitochondrial DNA disease: new options for prevention. Hum Mol Genet 2011; 20: R168-R174.
98. Craven L, Tuppen HA, Greggains GD, Harbottle SJ, Murphy JL, Cree LM et al. Pronuclear transfer in human embryos to prevent transmission of mitochondrial DNA disease. Nature 2010; 465(7294): U82-U89.
99. Tachibana M, Sparman M, Sritanaudomchai H, Ma H, Clepper L, Woodward J et al. Mitochondrial gene replacement in primate offspring and embryonic stem cells. Nature 2009; 461(7262): 367-372.
100. Tachibana M, Amato P, Sparman M, Woodward J, Sanchis DM, Ma H et al. Towards germline gene therapy of inherited mitochondrial diseases. Nature 2013; 493(7434): 627-631